| Autor: |
Faust, Jeremy Samuel, Meyerowitz-Katz, Gideon |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 7/15/2024, Vol. 79 Issue 1, p111-114, 4p |
| Abstrakt: |
The article focuses on the discrepancy between regulatory approval and medical insurance coverage for novel therapeutics, emphasizing that coverage often depends on cost-benefit analyses rather than just safety and efficacy. Topics include the impact of changing drug costs on insurance coverage, how pandemic-related changes in population immunity affect the perceived benefit of treatments over time, and the role of studies in assessing continued effectiveness and coverage appropriateness. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
